Stemline Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference

NEW YORK, Feb. 4, 2016 -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 4:00 PM ET. The conference is being held at the Waldorf Astoria Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701. A pivotal trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R; CD123) present on a wide range of hematologic cancers, is currently enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Data from the initial stage of this ongoing pivotal trial demonstrated high overall response rates, with multiple complete responses (CRs) and patients bridged to transplant. Patients continue to be followed for overall response, progression free survival (PFS) and overall survival (OS), and new patients continue to accrue into the study. Clinical studies with SL-401 are also open in additional malignancies including acute myeloid leukemia (AML) in complete remission with minimal residual disease (MRD) and high-risk myeloproliferative neoplasms (MPN). A clinical study with SL-701, an immunotherapy designed to activate the immune system to attack tumors, is currently accruing adult patients with second-line glioblastoma multiforme (GBM). SL-801, a novel oral small molecule reversible inhibitor of XPO1, has an open IND and is being advanced into clinical trials across multiple cancer types. For more information about Stemline Therapeutics, visit www.stemline.com.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT:  Investor Relations
          Stemline Therapeutics, Inc.
          750 Lexington Avenue
          Eleventh Floor
          New York, NY 10022
          Tel: 646-502-2307
          Email: [email protected]